Key Takeaways
- Novo Nordisk Canada is considering introducing lower-priced, renamed copies of its brand-name Ozempic and Wegovy drugs to compete with generic versions.
- Health Canada has approved the company’s submissions for Plosbrio and Poviztra, which are identical to Ozempic and Wegovy, respectively.
- Generic semaglutide drugs are unlikely to be approved for at least a few months due to the complexity of evaluating them.
- Novo Nordisk’s move is seen as a way to stay competitive in the market and potentially implement a new pricing strategy.
- Increased competition, whether from generic companies or lower-priced "branded options," would be welcome from a patient perspective.
Introduction to Novo Nordisk’s Strategy
Novo Nordisk Canada is considering a unique strategy to compete with generic versions of its brand-name Ozempic and Wegovy drugs. The company is planning to introduce renamed, lower-priced copies of the medications, which have been approved by Health Canada. According to Mark Johnson, a Health Canada spokesperson, the diabetes and weight-loss drugs, Plosbrio and Poviztra, are identical to Ozempic and Wegovy, respectively, with the only differences being the product names and packaging. This move is seen as a way for Novo Nordisk to stay competitive in the market and potentially implement a new pricing strategy.
The Regulatory Process
Health Canada is currently considering nine submissions from other drug companies to make generic semaglutide, the active ingredient in Ozempic, Wegovy, Plosbrio, and Poviztra. However, experts have cautioned that generic semaglutide drugs are unlikely to be approved for at least a few months. The evaluation process is complex because Novo Nordisk’s products were developed using biological processes, while the generic versions are made using chemical means. Johnson explained that generic semaglutide products are complex synthetic products that are pharmaceutically equivalent to the brand-name drug, but with possible differences that could impact safety and efficacy. The manufacturer must show that these differences do not affect the safety, efficacy, or quality of the generic drug compared to the brand-name drug.
Novo Nordisk’s Motivation
Kate Hanna, a spokesperson for Novo Nordisk Canada, stated that the company is considering introducing a version of semaglutide to compete with generics once they enter the Canadian market. Mina Tadrous, a pharmaceutical policy expert at the University of Toronto, called the potential move "an interesting play." Tadrous explained that due to the pricing structure in Canada, Novo Nordisk cannot simply lower the price of their brand-name product to allow generic market entry. Instead, the company is using this strategy to bypass that limitation and stay competitive. With the renamed and repackaged drugs, Novo Nordisk could implement a new pricing strategy, which would be a welcome development from a patient perspective.
Expert Insights
Shelita Dattani, a pharmacist and health-care consultant, stated that such a strategy would not be unprecedented but would be unusual. Dattani noted that increased competition, whether it’s from generic companies or lower-priced "branded options" by Novo Nordisk, would be welcome from a patient perspective. Ozempic and Wegovy can cost hundreds of dollars a month, but many Canadian patients don’t pay that out of pocket. Hanna explained that Ozempic is covered by the majority of private insurance plans and is included in all government-sponsored drug plans for adults diagnosed with Type 2 diabetes. While Wegovy is not covered by government-sponsored public drug plans, it has strong private insurance coverage, and the company continues to work to increase coverage for Canadians living with obesity.
Patient Accessibility
In an interview with The Canadian Press in December, Novo Nordisk Canada president Vince Lamanna said that more than a million patients in the country take the medications, and the company provides "financial and savings support" to some patients who don’t have insurance coverage. This support is crucial, as the high cost of these medications can be a significant barrier to access. With the potential introduction of lower-priced, renamed copies of Ozempic and Wegovy, patients may have more affordable options for accessing these life-changing medications. As the landscape of the pharmaceutical industry continues to evolve, it will be essential to monitor how Novo Nordisk’s strategy impacts patient accessibility and the overall market.